ATE522611T1 - Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper - Google Patents

Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper

Info

Publication number
ATE522611T1
ATE522611T1 AT08769934T AT08769934T ATE522611T1 AT E522611 T1 ATE522611 T1 AT E522611T1 AT 08769934 T AT08769934 T AT 08769934T AT 08769934 T AT08769934 T AT 08769934T AT E522611 T1 ATE522611 T1 AT E522611T1
Authority
AT
Austria
Prior art keywords
methods
immolobulingens
engodic
inhibiting
compositions
Prior art date
Application number
AT08769934T
Other languages
German (de)
English (en)
Inventor
Ronald Buelow
Original Assignee
Omt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40111008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522611(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omt Inc filed Critical Omt Inc
Application granted granted Critical
Publication of ATE522611T1 publication Critical patent/ATE522611T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
AT08769934T 2007-06-01 2008-05-30 Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper ATE522611T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94161907P 2007-06-01 2007-06-01
US4432408P 2008-04-11 2008-04-11
PCT/US2008/065419 WO2008151081A1 (en) 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies

Publications (1)

Publication Number Publication Date
ATE522611T1 true ATE522611T1 (de) 2011-09-15

Family

ID=40111008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08769934T ATE522611T1 (de) 2007-06-01 2008-05-30 Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper

Country Status (21)

Country Link
US (6) US8703485B2 (https=)
EP (4) EP3382022A1 (https=)
JP (6) JP5823690B2 (https=)
KR (4) KR101703299B1 (https=)
CN (1) CN101784664B (https=)
AT (1) ATE522611T1 (https=)
AU (1) AU2008259939B2 (https=)
CA (2) CA3054224C (https=)
CY (1) CY1120383T1 (https=)
DK (3) DK2602323T3 (https=)
ES (3) ES2393826T3 (https=)
HR (1) HRP20180506T1 (https=)
HU (1) HUE037302T2 (https=)
IL (2) IL202302A (https=)
LT (1) LT2602323T (https=)
NZ (1) NZ581396A (https=)
PL (3) PL2602323T3 (https=)
PT (3) PT2336329E (https=)
SG (2) SG10201509853UA (https=)
SI (1) SI2602323T1 (https=)
WO (1) WO2008151081A1 (https=)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
DK2602323T3 (en) * 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
JP2012501641A (ja) * 2008-09-08 2012-01-26 セレクティス グルタミンシンセターゼ遺伝子からのｄｎａ標的配列を切断するメガヌクレアーゼ変異型及びその使用
EP2346994B1 (en) * 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR102203727B1 (ko) * 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
KR20190107761A (ko) 2011-03-09 2019-09-20 셀 시그널링 테크놀러지, 인크. 모노클로날 항체를 생성하는 방법 및 시약
KR102068107B1 (ko) * 2011-04-27 2020-01-20 아미리스 인코퍼레이티드 게놈 변형 방법
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
AU2012312260B2 (en) * 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
IN2014DN09261A (https=) 2012-04-25 2015-07-10 Regeneron Pharma
CN104540382A (zh) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
HRP20231356T1 (hr) * 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
WO2014172458A1 (en) * 2013-04-16 2014-10-23 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
FI3137504T3 (fi) 2014-04-30 2023-08-07 Hanall Biopharma Co Ltd Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
RS60359B1 (sr) 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
US20170058052A1 (en) * 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
SI3558369T1 (sl) 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba
NZ755816A (en) 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
KR20200044094A (ko) 2017-09-13 2020-04-28 테네오바이오, 인코포레이티드 엑토효소에 결합하는 중쇄 항체
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
RU2020124623A (ru) 2017-12-27 2022-01-27 Тенеобио, Инк. Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20210021002A (ko) * 2018-06-13 2021-02-24 크리스탈 바이오사이언스 주식회사 다중 이황화 브릿지에 의해 안정화되고 유전자 변환에 의해 다양화되는 긴 cdr-h3s로 항체를 만드는 트랜스제닉 닭
US12102070B2 (en) * 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
PL3823990T3 (pl) 2018-07-20 2026-04-20 TeneoTwo, Inc. Przeciwciała łańcucha ciężkiego wiążące się z cd19
CN112955463B (zh) 2018-08-01 2024-07-05 赛福伦有限责任公司 抗cxcr2抗体及其用途
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
EP3972997A1 (en) 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
CA3155930A1 (en) 2019-09-27 2021-04-01 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
AU2021263448B2 (en) 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
EP4247497A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
WO2022106663A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
US20250179175A1 (en) 2022-03-09 2025-06-05 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1992001043A1 (en) 1990-07-10 1992-01-23 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE4119749A1 (de) 1991-06-15 1992-12-17 Claas Ohg Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5795974A (en) 1993-12-10 1998-08-18 University Of Utah Research Foundation Mycoplasma arthritidis superantigen
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6372956B1 (en) * 1998-12-31 2002-04-16 The J. David Gladstone Institutes Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
JP2004500843A (ja) * 2000-04-24 2004-01-15 ワイエス トランスジェニック動物
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) * 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2457317A1 (en) 2001-08-20 2003-02-27 Merck & Co., Inc. Transgenic rodents as animal models for modulation of b1 bradykinin receptor protein
ATE466088T1 (de) * 2001-09-14 2010-05-15 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20040158880A1 (en) * 2003-02-05 2004-08-12 Roland Buelow Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
EP1644417B1 (en) 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005019463A1 (en) * 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) * 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
JP4862119B2 (ja) 2004-03-04 2012-01-25 大日本住友製薬株式会社 ラット胚性幹細胞
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US20080184380A1 (en) * 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
NZ554824A (en) * 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
EP1854473A1 (en) 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2327771A1 (en) 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
EP2840892B1 (en) * 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences

Also Published As

Publication number Publication date
CN101784664A (zh) 2010-07-21
SG182144A1 (en) 2012-07-30
PT2336329E (pt) 2012-12-24
DK2602323T3 (en) 2018-04-16
JP2015204840A (ja) 2015-11-19
CN101784664B (zh) 2013-04-10
CY1120383T1 (el) 2019-07-10
CA3054224C (en) 2026-03-03
JP5823690B2 (ja) 2015-11-25
EP2336329B1 (en) 2012-10-10
IL202302A (en) 2013-07-31
KR101661357B1 (ko) 2016-09-29
US20210253673A1 (en) 2021-08-19
PT2152880E (pt) 2011-12-15
CN102850452A (zh) 2013-01-02
KR20100037027A (ko) 2010-04-08
AU2008259939B2 (en) 2014-03-13
DK2152880T3 (da) 2011-11-28
EP2336329A1 (en) 2011-06-22
EP2336329B8 (en) 2012-11-21
ES2372718T3 (es) 2012-01-25
AU2008259939A1 (en) 2008-12-11
JP2022118217A (ja) 2022-08-12
US20160311888A1 (en) 2016-10-27
EP2152880A1 (en) 2010-02-17
US20120090041A1 (en) 2012-04-12
CA2688834A1 (en) 2008-12-11
KR101886610B1 (ko) 2018-08-09
PL2336329T3 (pl) 2013-04-30
HK1135138A1 (en) 2010-05-28
ES2664218T3 (es) 2018-04-18
KR101703299B1 (ko) 2017-02-06
CA3054224A1 (en) 2008-12-11
JP2020125360A (ja) 2020-08-20
PT2602323T (pt) 2018-04-02
US9388233B2 (en) 2016-07-12
EP3382022A1 (en) 2018-10-03
IL202302A0 (en) 2011-08-01
US20090098134A1 (en) 2009-04-16
JP6712254B2 (ja) 2020-06-17
US10072069B2 (en) 2018-09-11
US8907157B2 (en) 2014-12-09
PL2152880T3 (pl) 2012-03-30
IL220209A0 (en) 2012-07-31
SI2602323T1 (en) 2018-05-31
JP2018000201A (ja) 2018-01-11
DK2336329T3 (da) 2013-01-07
US8703485B2 (en) 2014-04-22
CA2688834C (en) 2020-01-07
WO2008151081A1 (en) 2008-12-11
EP2602323B1 (en) 2018-02-28
US20100212035A1 (en) 2010-08-19
KR20150101475A (ko) 2015-09-03
US20190169270A1 (en) 2019-06-06
KR20180090395A (ko) 2018-08-10
HUE037302T2 (hu) 2018-08-28
NZ581396A (en) 2012-07-27
KR20170016518A (ko) 2017-02-13
WO2008151081A8 (en) 2010-02-04
HRP20180506T1 (hr) 2018-05-04
KR102096731B1 (ko) 2020-04-02
JP2014027947A (ja) 2014-02-13
EP2152880A4 (en) 2010-06-16
PL2602323T3 (pl) 2018-06-29
JP2010529042A (ja) 2010-08-26
ES2393826T3 (es) 2012-12-28
LT2602323T (lt) 2018-04-10
EP2602323A1 (en) 2013-06-12
IL220209A (en) 2013-11-28
JP6220827B2 (ja) 2017-10-25
SG10201509853UA (en) 2015-12-30
EP2152880B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
ATE522611T1 (de) Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper
ATE473224T1 (de) Verfahren zur herstellung von nebivolol
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EP1833992A4 (en) IMMUNOGENIC PCV2 COMPOSITIONS AND METHODS OF PRODUCTION THEREOF
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
ATE491794T1 (de) Zusammensetzung und verfahren zur herstellung von steviolglykosiden
ATE535568T1 (de) Verfahren zur herstellung von polyethylenzusammensetzungen
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
EP3269737C0 (en) ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
ATE538816T1 (de) Verfahren zur herstellung eines bioaktiven implantats
PH12013502205A1 (en) Antibodies to il-6 and their uses
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP3438235C0 (en) METHOD FOR MANUFACTURED WAXY SOLID CLEANING COMPOUNDS UNDER PRESS
ATE523556T1 (de) Modifizierte polymerzusammensetzungen, modifikationsverfahren und mittel zur erzeugung freier radikale
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
ATE531784T1 (de) Verfahren zur herstellung von sapucainha-öl oder butter, kosmetische oder pharmazeutische zusammensetzung und verwendung des sapucainha-öls oder der sapucainha-butter,
WO2011025883A3 (en) Natural igm antibodies
DE502007003652D1 (de) Verwendung von nitratsalzen zur unterdrückung störender gerüche
ATE459610T1 (de) Verfahren zur herstellung von alkenylbernsteinsäureanhydriden
SG142293A1 (en) Method for producing anti-idiotypic antibodies
AT504611A3 (de) Verfahren zur herstellung von über keilzinkenverbindungen zusammengesetzten werkstücken bestehenden bauelementen und vorrichtung zur durchführung dieses verfahrens
ATE498601T1 (de) Neues verfahren zur herstellung von timberon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2152880

Country of ref document: EP